G-Protein Coupled Receptors Market is expected to cross USD 4,200 Million by 2025 at a CAGR of 7.1% during the forecast period.
The growing use of G-protein coupled receptors in medicate disclosure and advancement forms is set to drive the demand of G protein-coupled receptors.
G-protein coupled receptors are most commonly prescribed for the treatment of cardiovascular disease, oncology, immunology, respiratory system, central nervous system (CNS), and others. GPCRs (G-protein coupled receptors) play a physiological role in the regulation of cardiac function in both health and disease and thus represent one of the largest class of surface receptors targeted by drugs.
There is an increase in government support in R&D activities in the global G-protein coupled receptors market.
The government is supporting research & development for biosensors, orphan drug receptors, sedate targets, and high-throughput screening methods to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP).
An increasing number of allosteric modulators, biological drugs, and biased agonists that target the receptors accelerate the demand for assays in G-protein coupled receptors market.
- The increasing number of drugs under clinical and preclinical studies that target these receptors. Approximately, in 2018, there were 19% of drugs under clinical trial phase 1 which targets G protein-coupled receptors
- Existence of a variety of agents that stimulate GPCR activity. The drugs salmeterol and albuterol, bind and activate beta-adrenergic GPCRs, stimulate airway opening in the lungs and thus are used in the treatment of some respiratory conditions, including chronic obstructive pulmonary disease and asthma.
- The growing use of G-protein coupled receptors in medicate disclosure and advancement forms.
- Increasing number of allosteric modulators, biological drugs, and biased agonists that target these receptors.
- Presence of a large number of approved drugs that target G-protein coupled receptors. In 2018, there were approximately 700 approved drugs that target G protein-coupled receptors (GPCRs).
- High cost involved in the maintenance of GPCR cell lines.
- Stringent government policies
- Cell Lines: Cell lines play a significant role in the cellular impedance assays for the detection of GPCR targets.
- Detection Kits: Fastest segment as detection kits are easy to use, robust, and highly sensitive products to evaluate the activity through different pathways.
- Cell Culture Reagents: Largest segment as it is one of the most conventional and affordable ways of use with effective
- Ligands: Ligands stabilize G protein-coupled receptors and affect its functions. GPCR binds with many different types of ligands.
By Assay Type
- Calcium Functional Assays: Fastest segment. Due to the numerous advantages associated with the use of calcium flux assays. The benefits include high sensitivity, user configurability, ease in the estimation of calcium flux.
- cAMP Functional Assays: It is cyclic adenosine monophosphate (cAMP). It is an essential intracellular second messenger in GPCR.
- cGMP Assays: Acyclic guanosine monophosphate (cGMP) assay provides a competitive immunoassay for sensitive and quantitative determination of cGMP level in biological samples.
- GTP Gamma S Binding Assays: It can be used to differentiate agonist, antagonist, and inverse agonist activities.
- ß-Arrestin Functional Assays: It helps in the activation of GPCRs and helps in the regulation of other signaling molecules such as protein kinases.
- Internalization Assays: It monitors the internalization and recycling patterns of activated GPCRs.
- Others: Others include reporter gene assays, trafficking Assays.
- Cardiovascular System: Largest segment. The β-adrenergic receptors and angiotensin II receptors provide therapy for a wide range of cardiovascular disease, which includes coronary artery disease, hypertension, and heart failure. About 610,000 people die of heart disease in the US every year.
- Oncology: GPCR controls features of tumorgenesis, that includes immune cell-mediated function, invasion, proliferation at the secondary site. In 2018, approximately 1,735,350 new cases of cancer were diagnosed in the US.
- Immunology: GPCRs bind to various metabolites and transmit signals that are important for proper immune and metabolic functions.
- Respiratory System: GPCRs mediates various airway smooth muscle functions that include contraction, growth, and synthetic functions that orchestrate airway inflammation and promote remodeling of the airway.
- Central Nervous System: GPCRs plays a vital role in the pathophysiology of different diseases and disorders that include anxiety, depression, schizophrenia, and epilepsy.
- Others: Others include metabolism and inflammation.
- Americas: The largest regional market owing to the strategic investments in cancer research that would drive the growth of G protein-coupled receptors market.
- Europe: Rising number of approved drugs that target GPCRs would drive the demand for G protein-coupled receptors market in this region. In November 2017, 134 GPCR targets for drugs were approved in European Union, and 128 targets were listed in the food and drug administration (FDA) orange book, thus driving the growth of G protein-coupled receptors market in this region.
- Asia-Pacific: Fastest segment. Due to the presence of several emerging companies such as HD Biosciences Co. Ltd., NB Health Laboratory. An increasing number of growth initiatives taken by companies to improve their market presence will drive the growth of G protein-coupled receptor in this region.
- Middle East & Africa: Increasing healthcare expenditure and rising government funding drive the demand for the G-protein coupled receptors market in this region.
- Thermo Fisher Scientific, Inc. (US)
- Abcam PLC (UK)
- QIAGEN (Germany)
- Promega Corporation (US)
- PerkinElmer Inc. (US)
- Enzo Life Sciences, Inc. (US)
- BD (US)
- Cisbio (Europe)
- Merck Group (Germany)
- HD Biosciences Co., Ltd (China)
2025: USD 4,200 Million 2027: Significant Value
Value (USD Million)
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Product, Assay Type, Application
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Thermo Fisher Scientific, Inc. (US), Abcam PLC (UK), QIAGEN (Germany), Promega Corporation (US), PerkinElmer Inc. (US), Enzo Life Sciences, Inc. (US), BD (US)
Cisbio (Europe), Merck Group (Germany), HD Biosciences Co., Ltd (China)
Key Market Opportunities
New product launches and R&D Amongst major key Players
Key Market Drivers
The increasing number of drugs under clinical and preclinical studies that target these receptors Existence of a variety of agents that stimulate GPCR activity. The growing use of G-protein coupled receptors in medicate disclosure and advancement forms Increasing number of allosteric modulators, biological drugs, and biased agonists that target these receptors. Presence of a large number of approved drugs that target G-protein coupled receptors.
Frequently Asked Questions (FAQ) :
The global G-protein coupled receptors market is projected to reach a valuation of USD 4,200 MN by 2025.
The global G-protein coupled receptors market is projected to grow at approximately 7.1% CAGR during forecast period (2019-2025).
Rising numbers of drugs under clinical and preclinical studies, targeting these receptors.
North America holds the largest share in the global G-protein coupled receptors market, followed by Europe and the Asia Pacific, respectively.
Abcam PLC (UK), Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), PerkinElmer Inc. (US), Promega Corporation (US), Enzo Life Sciences, Inc. (US), Cisbio (Europe), BD (US), Merck Group (Germany), and HD Biosciences Co., Ltd (China), are some of the major players operating in the G-protein coupled receptors market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.